Find comprehensive information on Invasive Ductal Carcinoma of the Right Breast, including clinical documentation requirements, ICD-10 codes C50.911 and C50.919, medical coding guidelines, histology, pathology reports, staging, treatment options, and best practices for healthcare professionals. Learn about diagnostic criteria, surgical procedures like lumpectomy and mastectomy, and relevant medical terminology for accurate and efficient documentation of this right breast cancer diagnosis. This resource supports accurate clinical records and optimal patient care.
Also known as
Malignant neoplasm of breast
Covers various invasive breast cancers.
Secondary malignant neoplasm of breast
Specifies breast cancer that spread from another site.
Personal history of malignant neoplasm of breast
Indicates a past diagnosis of breast cancer.
Malignant neoplasms
Broader category encompassing all malignant cancers.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the ductal carcinoma in situ (DCIS)?
When to use each related code
| Description |
|---|
| Invasive Ductal Carcinoma Right Breast |
| Ductal Carcinoma In Situ Right Breast |
| Invasive Lobular Carcinoma Right Breast |
Q: What are the key prognostic factors for staging Invasive Ductal Carcinoma of the Right Breast and how do they influence treatment decisions?
A: Staging Invasive Ductal Carcinoma of the Right Breast relies on several key prognostic factors, including tumor size (T), lymph node involvement (N), and the presence of distant metastases (M), collectively known as the TNM system. Beyond TNM, histological grade, hormone receptor status (ER, PR), HER2 status, and Ki-67 proliferation index are crucial. These factors influence treatment decisions significantly. For example, hormone receptor-positive tumors often benefit from endocrine therapy, while HER2-positive tumors are candidates for targeted HER2 therapies. Tumor size and nodal status guide surgical decisions, including breast conservation versus mastectomy and the extent of axillary surgery. Consider implementing a multidisciplinary approach involving surgeons, medical oncologists, radiation oncologists, and pathologists to personalize treatment based on these individual prognostic factors. Explore how integrating genomic assays can further refine prognostication and treatment selection for Invasive Ductal Carcinoma of the Right Breast.
Q: How do I differentiate between Invasive Ductal Carcinoma of the Right Breast and other right breast lesions on imaging (mammography, ultrasound, MRI) and what are the recommended next steps for confirmation?
A: Differentiating Invasive Ductal Carcinoma of the Right Breast from other breast lesions on imaging requires careful assessment of features such as spiculated margins, architectural distortion, asymmetric density, and abnormal enhancement patterns. While mammography is often the initial screening tool, ultrasound is crucial for characterizing masses and assessing vascularity. MRI offers greater sensitivity for detecting multifocal or multicentric disease, particularly in dense breasts. However, imaging findings alone are not definitive. A core needle biopsy or fine-needle aspiration biopsy is mandatory for histopathological confirmation and determination of receptor status, which are essential for accurate diagnosis and treatment planning. Learn more about the specific imaging characteristics of Invasive Ductal Carcinoma and the role of advanced imaging techniques like contrast-enhanced mammography in improving diagnostic accuracy.
Patient presents with a complaint of a palpable lump in the right breast. On physical examination, a firm, irregular mass is noted in the upper outer quadrant of the right breast. The overlying skin exhibits dimpling suggestive of peau d'orange. Ipsilateral axillary lymphadenopathy is palpable. Ultrasound-guided biopsy of the right breast mass confirms the diagnosis of invasive ductal carcinoma. Immunohistochemical staining results are pending. Differential diagnoses included fibroadenoma, breast cyst, and inflammatory breast cancer. The patient's medical history is significant for hypertension and hyperlipidemia. Family history is positive for breast cancer in a first-degree relative. Patient was counseled regarding treatment options, including surgical intervention (lumpectomy, mastectomy), radiation therapy, chemotherapy, hormone therapy, and targeted therapy. Staging workup, including chest X-ray, CT scan of the chest, abdomen, and pelvis, and bone scan, will be performed to assess the extent of disease. Referral to a medical oncologist and a radiation oncologist is made. Patient education materials on breast cancer, its treatment, and potential side effects were provided. ICD-10 code C50.919, right breast, is assigned. CPT codes for the biopsy and imaging studies will be documented separately. Follow-up appointment is scheduled in one week to discuss treatment plan based on staging results. Plan includes genetic testing and counseling regarding BRCA mutation status. Keywords: Breast cancer, invasive ductal carcinoma, right breast mass, lumpectomy, mastectomy, radiation therapy, chemotherapy, hormone therapy, targeted therapy, breast biopsy, axillary lymphadenopathy, peau d'orange, ultrasound, mammography, ICD-10 C50.919, CPT codes, medical oncology, radiation oncology, breast cancer treatment, BRCA mutation, genetic testing.